公开(公告)号：US11421011B2

公开(公告)日：2022-08-23

申请号：US16613732

申请日：2018-05-18

Applicant: ModernaTX, Inc.

Inventor： Ankita Mishra ,  Joshua Frederick ,  Sushma Gurumurthy

IPC: C07K14/54 ,  A61K9/51 ,  A61K38/00

Abstract: The present disclosure relates to polynucleotides encoding tethered interleukin-12 (IL-12) polypeptides comprising an IL-12 polypeptide and a membrane domain. The present disclosure also relates to vectors comprising the polynucleotides; host cells comprising the polynucleotides or vectors, polypeptides encoded by the polynucleotides; compositions comprising the polynucleotides, vectors, host cells, or polypeptides and a delivery agent; and uses thereof, including treatment of cancer.

公开(公告)号：US11071716B2

公开(公告)日：2021-07-27

申请号：US17071685

申请日：2020-10-15

Applicant: ModernaTX, Inc.

Inventor： Joshua Frederick ,  Ailin Bai ,  Vladimir Presnyak ,  Stephen G. Hoge ,  Kerry Benenato ,  Iain McFadyen ,  Ellalahewage Sathyajith Kumarasinghe ,  Susannah Hewitt

IPC: A61K48/00 ,  A61K9/51 ,  A61K38/17 ,  A61K38/20 ,  A61K9/00 ,  A61K39/39 ,  A61K45/06 ,  A61K9/127 ,  C07K14/54 ,  C07K14/545 ,  C07K14/705 ,  A61K31/7088 ,  A61K31/7115 ,  A61P35/00 ,  A61K39/395 ,  A61K39/00 ,  B82Y5/00 ,  C12N15/88

Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

公开(公告)号：US20190241658A1

公开(公告)日：2019-08-08

申请号：US16068787

申请日：2017-01-10

Applicant: ModernaTX, Inc.

Inventor： Joshua Frederick

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2818 ,  A61K2039/505 ,  A61K2039/53 ,  A61P35/00 ,  C07K2317/14 ,  C07K2317/76

Abstract: The invention relates to compositions and methods for their preparation, manufacture and therapeutic use wherein those composition comprise of one or more polynucleotides (e.g., mRNAs) encoding a binding molecule (e.g., an antibody or an antigen binding portion thereof) which specifically binds to CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). The therapeutic methods disclosed herein comprise, e.g., the administration of one or more mRNAs encoding an anti-CTLA-4 antibody or an antigen-binding portion thereof for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the disclosed mRNA or mRNAs encoding the anti-CTLA-4 antibody or an antigen-binding portion thereof are administered intratumorally. When several mRNAs are used to express the disclosed anti-CTLA-4 antibodies or antigen-binding portions thereof, the ratio of mRNAs can be the same or different.

公开(公告)号：US10322090B2

公开(公告)日：2019-06-18

申请号：US16184282

申请日：2018-11-08

Applicant: ModernaTX, Inc.

Inventor： Joshua Frederick ,  Ailin Bai ,  Vladimir Presnyak ,  Stephen Hoge ,  Kerry Benenato ,  Iain Mcfadyen ,  Ellalahewage Sathyajith Kumarasinghe ,  Susannah Hewitt

IPC: A61K48/00 ,  A61K9/51 ,  A61K38/17 ,  A61K38/20 ,  A61K9/00 ,  A61K39/39 ,  A61K45/06 ,  A61K9/127 ,  C07K14/54 ,  C07K14/545 ,  C07K14/705 ,  A61P35/00 ,  A61K39/395 ,  A61K39/00 ,  B82Y5/00 ,  C12N15/88

Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

公开(公告)号：US10285950B2

公开(公告)日：2019-05-14

申请号：US16227810

申请日：2018-12-20

Applicant: ModernaTX, Inc.

Inventor： Joshua Frederick ,  Ailin Bai ,  Vladimir Presnyak ,  Stephen Hoge ,  Kerry Benenato ,  Iain McFadyen ,  Ellalahewage Sathyajith Kumarasinghe ,  Susannah Hewitt

IPC: A61K48/00 ,  A61K9/51 ,  C07K14/54 ,  A61K38/17 ,  A61K38/20 ,  C07K14/705 ,  A61P35/00 ,  A61K39/395 ,  A61K9/00 ,  A61K39/00

Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

公开(公告)号：US20190060246A1

公开(公告)日：2019-02-28

申请号：US16184282

申请日：2018-11-08

Applicant: ModernaTX, Inc.

Inventor： Joshua Frederick ,  Ailin Bai ,  Vladimir Presnyak ,  Stephen Hoge ,  Kerry Benenato ,  Iain Mcfadyen ,  Ellalahewage Sathyajith Kumarasinghe ,  Susannah Hewitt

IPC: A61K9/51 ,  C07K14/705 ,  A61P35/00 ,  C07K14/54 ,  C07K14/545 ,  A61K9/00 ,  A61K9/127 ,  A61K38/17 ,  A61K48/00 ,  A61K45/06 ,  A61K39/395 ,  A61K39/39 ,  A61K38/20 ,  A61K39/00

Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).